Oligometastatic Disease

  • Vivek Verma
  • Waqar Haque
  • Gary D. Lewis
  • E. Brian Butler
  • Bin S. TehEmail author
Part of the Medical Radiology book series (MEDRAD)


Metastatic cancer patients represent a highly heterogeneous cohort with widely differing prognoses. The application of local, metastasis-directed therapies is becoming increasingly appealing, but controversies regarding patients most likely to benefit from these interventions remain. This chapter aims to evaluate the phenomenon of the oligometastatic state, rationales for utilizing local therapy (surgical and radiotherapeutic), as well as summarize the available evidence thereof. A discussion on interactions of local therapy with immunotherapy, ongoing clinical trials, and optimal patient selection is also conducted.


  1. Andratschke N, Alheid H, Allgauer M et al (2018) The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer 18:283CrossRefGoogle Scholar
  2. Ashworth AB, Senan S, Palma DA et al (2014) An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non–small-cell lung cancer. Clin Lung Cancer 15:346–355CrossRefGoogle Scholar
  3. Azzam G, Lanciano R, Arrigo S et al (2015) SBRT: an opportunity to improve quality of life for oligometastatic prostate cancer. Front Oncol 5:101CrossRefGoogle Scholar
  4. Chudgar NP, Brennan MF, Munhoz RR et al (2017) Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. J Thorac Cardiovasc Surg 154:319–330CrossRefGoogle Scholar
  5. Collen C, Christian N, Schallier D et al (2014) Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Ann Oncol 25:1954–1959CrossRefGoogle Scholar
  6. Dawood S, Broglio K, Gonzalez-Angulo AM et al (2008) Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 26:4891–4898CrossRefGoogle Scholar
  7. De Cos Escuin JS, Vecente CD, Penafiel JC et al (2004) Overall long-term survival in lung cancer analyzed in 610 unselected patients. Arch Bronconeumol 40:268–274Google Scholar
  8. De Ruysscher D, Wanders R, van Baardwijk A et al (2012) Radical treatment of non–small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol 7:1547–1555Google Scholar
  9. Falkson G, Gelman RS, Leone L et al (1990) Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies. Cancer 66:1621–1629CrossRefGoogle Scholar
  10. Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318CrossRefGoogle Scholar
  11. Formenti SC, Demaria S (2009) Systemic effects of local radiotherapy. Lancet Oncol 10:718–726CrossRefGoogle Scholar
  12. Fry WA, Phillips JL, Menck HR (1999) Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 86:1867–1876CrossRefGoogle Scholar
  13. Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100:44–52CrossRefGoogle Scholar
  14. Gomez DR, Blumenschein GR Jr, Lee JJ et al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17:1672–1682CrossRefGoogle Scholar
  15. Gomez DR, Tang C, Zhang J et al (2018) Local consolidative therapy (LCT) improves overall survival (OS) compared to maintenance therapy/observation in oligometastatic non-small cell lung cancer (NSCLC): final results of a multicenter, randomized, controlled phase 2 trial. Int J Radiat Oncol Biol Phys 102:LBA3CrossRefGoogle Scholar
  16. Gore EM, Hu C, Sun AY et al (2017) Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC): NRG oncology RTOG 0937. J Thorac Oncol 12:1561–1570CrossRefGoogle Scholar
  17. Greenberg PA, Hortobagyi GN, Smith TL et al (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197–2205CrossRefGoogle Scholar
  18. Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10CrossRefGoogle Scholar
  19. Hughes KS, Simon R, Songhorabodi S et al (1986) Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 100:278–284PubMedGoogle Scholar
  20. Husain ZA, Sahgal A, De Salles A et al (2017) Stereotactic body radiotherapy for de novo spinal metastases: systematic review. J Neurosurg Spine 27:295–302CrossRefGoogle Scholar
  21. Iyengar P, Kavanagh BD, Wardak Z et al (2014) Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non–small-cell lung cancer. J Clin Oncol 32:3824–3830CrossRefGoogle Scholar
  22. Iyengar P, Wardak Z, Gerber DE et al (2018) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 4:e173501CrossRefGoogle Scholar
  23. Milano MT, Katz AW, Zhang H, Okunieff P (2012) Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83:878–886CrossRefGoogle Scholar
  24. Nordlinger B, Guiguet M, Vaillant JC et al (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 77:1254–1262CrossRefGoogle Scholar
  25. Owen D, Laack NN, Mayo CS et al (2014) Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases. Pract Radiat Oncol 4:e143–e149CrossRefGoogle Scholar
  26. Palma DA, Olson RA, Harrow S et al (2018) Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial. Int J Radiat Oncol Biol Phys 102:S3–S4CrossRefGoogle Scholar
  27. Pastorino U, Buyse M, Friedel G et al (1997) Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 113:37–49CrossRefGoogle Scholar
  28. Pawlik TM, Scoggins CR, Zorzi D et al (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715–722CrossRefGoogle Scholar
  29. Pfister DG, Johnson DH, Azzoli CG et al (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330–353CrossRefGoogle Scholar
  30. Radwan N, Phillips R, Ross A et al (2017) A phase II randomized trial of observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). BMC Cancer 17:453CrossRefGoogle Scholar
  31. Ranck MC, Golden DW, Corbin KS et al (2013) Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol 36:589–595CrossRefGoogle Scholar
  32. Rieber J, Streblow J, Uhlmann L et al (2016) Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-a pooled analysis of the German working group “stereotactic radiotherapy”. Lung Cancer 97:51–58CrossRefGoogle Scholar
  33. Ruers T, van Coevorden F, Punt CJ et al (2017) Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst 109:djx015PubMedCentralGoogle Scholar
  34. Rusthoven KE, Kavanagh BD, Burri SH et al (2009a) Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol:1579–1584Google Scholar
  35. Rusthoven KE, Kavanagh BD, Cardenes H et al (2009b) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27:1572–1578CrossRefGoogle Scholar
  36. Shaverdian N, Lisberg AE, Bornazyan K et al (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18:895–903CrossRefGoogle Scholar
  37. Theelen W, Lalezari F, de Vries J et al (2018) Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: the PEMBRO-RT study. J Clin Oncol 36s:9023CrossRefGoogle Scholar
  38. Vanpouille-Box C, Alard A, Aryankalayil MJ et al (2017) DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun 8:15618CrossRefGoogle Scholar
  39. Wang T, Nelson RA, Bogardus A et al (2010) Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer 116:1518–1525CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Vivek Verma
    • 1
  • Waqar Haque
    • 2
  • Gary D. Lewis
    • 2
    • 3
  • E. Brian Butler
    • 2
  • Bin S. Teh
    • 2
    Email author
  1. 1.Department of Radiation OncologyAllegheny General HospitalPittsburghUSA
  2. 2.Department of Radiation OncologyHouston Methodist HospitalHoustonUSA
  3. 3.Department of Radiation OncologyUniversity of Texas Medical BranchGalvestonUSA

Personalised recommendations